NCT07671924Phase 2Recruiting

The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)

Study sponsor: Trevi Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-09Estimated
Enrollment · participants100Estimated
Source updated2026-11-05Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source